USA Illumina’s newly appointed CEO, Jacob Thaysen, will take the reins of the gene sequencing giant at the end of September. Falling heir to the difficulties that have plagued the company since its botched acquisition of cancer blood test maker Grail, Thaysen will have to confront the company’s legal tangles with…
See our Cookie Privacy Policy Here